der the Paperwork Reduction Act of 1995, no persons are required to res



DT03 Rec'd P

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

## **TRANSMITTAL FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

oond to a collection of information	uniess it displays a valid OMB control number
Application Number	10/517,563
Filing Date	December 7, 2004
First Named Inventor	Eva Steiness
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	57738(45487)

ENCLOSURES (Check all that apply)					
Fee Transn	nittal Form	Drawing(s)		After Allowance Communication to TC	
Fee Attached		Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences	
Amendmen	ıt/Reply	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
After	Final	Petition to Convert to a Provisional Application		Proprietary Information	
Affida	avits/declaration(s)	Power of Attorney, Revocation Change of Correspondence		Status Letter	
Extension of Time Request		Terminal Disclaimer		X Other Enclosure(s) (please Identify below):	
Express Abandonment Request		Request for Refund	į	PTO/SB/08 (12 Refs.) (1 page); Copy of International Search	
IDS (2 pages)		CD, Number of CD(s)  Report (7 pages); Return Receipt Postcar		Report (7 pages); Return Receipt Postcard.	
Certified Copy of Priority Document(s)		Landscape Table on CD			
	ssing Parts/ Application	Remarks			
	y to Missing Parts under FR 1.52 or 1.53				
;					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Name	EDWARDS & ANGELL, LLP				
Signature	Signature Lathyn a. Prispat, Pl.D.				
Printed name	Kathryn A. Piffat, Ph.D.				
Date	March 7, 2005		Reg. No.	34,901	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 7, 2005

BOS2\_480797.1



PTO/SB/92 (09-04) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/517,563

Attorney Docket No.: 57738(45487)

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

> MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

March 7, 2005 Date

Sharon Bizokas

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 439-4444

Telephone Number

Note:

Each paper must have its own certificate of mailing, or this certificate must identify

each submitted paper.

Transmittal (1 page)

Information Disclosure Statement (2 pages)

PTO/SB/08 (12 References) (1 page)

Copy of International Search Report (2 pages)

Return Receipt Postcard



I hereby certify that this corresponded ing deposited with the U.S. Postal Service with sufficient postage as Fire Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 7, 2005

Docket No.: 57738(45487) (PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

**Eva Steiness** 

Application No.: 10/517,563

Confirmation No.: N/A

Filed: December 7, 2004

Art Unit: N/A

For: **GLP-1 AND METHODS FOR TREATING** 

Examiner: Not Yet Assigned

DIABETES

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 CFR 1.97(b)(1)).

A copy of each reference on the PTO/SB/08 is attached.

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 57738(45487). A duplicate copy of this paper is enclosed.

Dated: March 7, 2005

Respectfully submitted,

Kathryn A. Piffat, Ph.D.

Registration No.: 34,901 EDWARDS & ANGELL; LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorney for Applicant

PTO/SB/08a/b (08-03) Approved for use arrough 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO Application Number 10/517,563 INFORMATION DISCLOSURE December 7, 2004 Filing Date STATEMENT BY APPLICANT First Named Inventor **Eva Steiness** Art Unit N/A (Use as many sheets as necessary) Not Yet Assigned Examiner Name 57738(45487) Sheet of Attorney Docket Number

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,358,924	3/19/02	Hoffmann	
	AB	US-6,344,180	2/5/02	Holst et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	ВА	WO 99 43708 A	9/2/99	Madsen et al.		П
	ВВ	WO 01 32158	5/10/01	Piper		
	BC	WO 01 04156	1/18/01	Larsen		
	BD	EP 1 329 458	7/23/03	Larsen		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not a considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.usplo.gov">www.usplo.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>		
	CA	Young et al., "Studies in Obese Diabetic (ob/ob, db/db) Mice, Diabetic Fatty Zucker Rats, and Diabetic Rhesus Monkeys (Macaca mulatto)", Diabetes, 48:1026-1034 (1999)			
	СВ	Juntti-Berggren et al., "The Antidiabetogenic Effect of GPL-1 Is Maintained During a 7-Day Treatment Period and Improves Diabetic Dyslipoproteinemia in NIDDM Patients", Diabetes Care, 19(11):1200-1206 (1996)			
	CC	Parkes et al., "Insulinotropic Actions of Exendin-4 and Glucagon-Like Peptide-1 In Vivo and In Vitro", Metabolism, 50(5):583-589 (2001)			
	CD	Burcelin et al., "Long-Lasting Antidiabetic Effect of a Dipeptidyl Peptidase IV-Resistant Analog of Glucagon-Like Peptide-1", Metabolism, 48(2):252-258 (1999)			
	CE	Ritzel et al., "A synthetic glucagons-like peptide-1 analog with improved plasma stability", Journal of Endocrinology, 159:93-102 (1998)			
	CF	Stoffers et al., "Insulinotropic Glucagon-Like Peptide 1 Agonists Stimulate Expression of Homeodomain Protein ID-1 and Increase Islet Size in Mouse Pancreas", Diabetes, 49:741-748 (2000)			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	· · ·
Signature	Considered	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.